Advisor Group Holdings, Inc. Zymeworks Inc. Transaction History

Advisor Group Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$4.82 - $7.7 $1,205 - $1,925	-250 Reduced 71.43%	100 $1,000
Q1 2022 May 04, 2022	SELL	$6.0 - $16.98 $3,540 - $10,018	-590 Reduced 62.77%	350 $3,000
Q3 2021 Nov 05, 2021	SELL	$27.35 - $37.28 $16,410 - $22,368	-600 Reduced 38.96%	940 $27,000
Q2 2021 Aug 02, 2021	SELL	$26.5 - $38.23 $291 - $420	-11 Reduced 0.71%	1,540 $53,000
Q1 2021 May 13, 2021	BUY	$29.83 - $56.81 $28,189 - $53,685	945 Added 155.94%	1,551 $49,000
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $202 - $240	6 Added 1.0%	606 $22,000
Q1 2020 May 18, 2020	BUY	$24.28 - $49.8 $14,568 - $29,880	600 New	600 $22,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $872M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.